Prostate Cancer
Active surveillance selection and 3-year durability in intermediate-risk prostate cancer following genomic testing.
September 9, 2024
Effect of PSMA PET/CT on the Use of Bone Scintigraphy for Prostate Cancer at a University Hospital System.
September 9, 2024
Impact of TP53 loss-of-function alterations on the response to PSMA radioligand therapy in metastatic castration-resistant prostate cancer patients.
September 9, 2024
Development of prediction models based on risk scores for clinically significant prostate cancer on MRI/TRUS fusion biopsy.
September 6, 2024
PARP Inhibitor Addition to Androgen Receptor Pathway Inhibitors in Metastatic Castration-resistant Prostate Cancer Should Be Limited to BRCA Mutation Carriers.
September 6, 2024
The third symposium on treatment-induced neuroendocrine prostate cancer: insights and future directions.
September 5, 2024
A Multi-Institutional Study of MR/US Fusion Guided Nanoparticle Directed Focal Therapy for Prostate Ablation.
September 5, 2024
Talazoparib for the treatment of prostate cancer.
September 5, 2024
PSMA PET improves characterization of dural-based intracranial lesions in patients with metastatic prostate cancer.
September 5, 2024
Pelvic Lymph Node Dissection: A Comparison Among Extraperitoneal Single-port and Transperitoneal Multiport Radical Prostatectomy-A Single-center Experience.
September 5, 2024
The Man Van: A pilot study of using mobile targeted case-finding to address health inequalities in prostate cancer.
September 5, 2024
The Proteogenomics of Prostate Cancer Radioresistance.
September 5, 2024